Krishna Institute of Medical Sciences Limited (KIMS) has intimated the stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the acquisition of a stake in Ushahkal Abhinav Specialty Hospital LLP.

Nature of the Event

On 29th October 2026, the company executed definitive agreements and completed the acquisition of a 5.82% stake in Ushahkal Abhinav Specialty Hospital LLP (Sangli), an Operations & Maintenance (O&M) entity. This acquisition was pursuant to a board resolution that had previously approved the proposal for acquisition of up to 6.00% stake.

Key Quantitative Figures

The aggregate consideration for the acquisition is ₹15.00 crore (Rupees Fifteen Crore only). The acquisition represents a 5.82% stake in the target LLP.

Dates of Action

The board of directors had previously approved the proposal. The definitive agreements were entered into and the consideration was remitted on 29th October 2026.

Parties Involved

  • Acquirer: Krishna Institute of Medical Sciences Limited (KIMS)
  • Target Entity: Ushahkal Abhinav Specialty Hospital LLP (UAIMS)
  • Valuation Advisor: BDO Valuation Advisory LLP (provided valuation report dated 5th October 2026)

Target Entity Details

Ushahkal Abhinav Specialty Hospital LLP is incorporated under the laws of India with its registered office at C. S. No. 105/1, Near Takshila School, Dhamani Road, Sangli – 416416, Maharashtra. The entity was founded in 2022 and incorporated on 25th November 2016.

Financial Performance (Rs. in Crore):

  • FY 2025-26: Turnover: 80.42, PAT: -23.59, Networth: 116.42
  • FY 2024-25: Turnover: 73.55
  • FY 2023-24: Turnover: 64.51

Operational Details:

  • State-of-the-art quaternary care facility
  • Current capacity: 316 beds
  • Potential for expansion to over 500 beds
  • Campus spans 4 acres with high floor-area-to-bed ratio
  • Presence: Sangli, Maharashtra, India

Purpose and Rationale

The acquisition is described as a "strategic investment" by KIMS. The transaction does not fall under related party transactions, and no promoters/promoter group/group companies have any interest in the entity being acquired.

Transaction Details

  • Consideration Type: Cash consideration
  • Funding Method: Primary infusion
  • Valuation Basis: BDO Valuation Advisory LLP report dated 5th October 2026
  • Percentage Acquired: 5.82% of total stake

Regulatory Approvals

No governmental or regulatory approvals are required for this acquisition as stated in the disclosure.

Additional Information

The disclosure has been uploaded on the company's website at: https://www.kimshospitals.com/investors/ under Disclosures under Regulation 62 of the SEBI (LODR) Regulations, 2015 > Intimations filed by the Company > Intimations under Regulation 30.